Drugs in Dev. Ophthalmology
Preclinical
United Kingdom 
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Negev Labs
Deal Size : Undisclosed
Deal Type : Acquisition
Negev Labs Announces Licensing and Psychedelic Research Collaborations
Details : The acquisition of Beckley Psytech's Ophthalmology development program aligns with Negev's mission to develop the full therapeutic potential of neuroplastogens.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Negev Labs
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akari Therapeutics Gets FDA Pre-IND Feedback on PAS-nomacopan For Geographic Atrophy
Details : PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 (LTB4) product candidate for intravitreal treatment of geographic atrophy (GA).
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Astellas Venture Management
Deal Size : $46.0 million
Deal Type : Series A Financing
Mogrify Extends Series A Financing to $46 Million USD
Details : The financing will support advancement of Mogrify’s dedicated pipeline of in vivo reprogramming therapies through pre-clinical translation, continued platform optimization, and facilitation of new and existing biopharma collaborations.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Astellas Venture Management
Deal Size : $46.0 million
Deal Type : Series A Financing
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Gimv
Deal Size : $78.9 million
Deal Type : Series A Financing
Details : With the financing, CTx will continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001. CTx001 is a highly innovative AAV gene therapy for the treatment of Geograpic Atrophy (GA) secondary to dry age-related ma...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 17, 2023
Lead Product(s) : Exagamglogene Autotemcel
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Gimv
Deal Size : $78.9 million
Deal Type : Series A Financing
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 30, 2022
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : AmbioPharm
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The new data showing extended dose intervals, together with data previously presented, showing LTB4 inhibition by PAS-nomacopan may also reduce risk of sight-threatening CNV, suggest PAS-rVA576(nomacopan) may be a potential novel and effective treatment ...
Product Name : Coversin
Product Type : Protein
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Thinkequity
Deal Size : $2.5 million
Deal Type : Public Offering
OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing
Details : OKYO intends to use the net proceeds from this Offering: (i) to advance OK-101 to the filing of an IND to treat DED; (ii) to fund the initial Phase 2 clinical trial of OK-101 in DED patients; and (iii) for working capital and other general corporate purp...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
May 19, 2022
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Thinkequity
Deal Size : $2.5 million
Deal Type : Public Offering
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Thinkequity
Deal Size : $2.5 million
Deal Type : Public Offering
OKYO Pharma Limited Announces Pricing of Public Offering and Nasdaq Listing
Details : OKYO Pharma intends to use the net proceeds of the offering to advance OK-101 to the filing of an IND to treat DED, to fund the initial Phase 2 clinical trial of OK-101 in DED patients, and the remaining proceeds for working capital and other general cor...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
May 16, 2022
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Thinkequity
Deal Size : $2.5 million
Deal Type : Public Offering
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Presentation highlight OK-101, agonist of chemerin receptor ChemR23, ability to reduce neuropathic corneal pain in mouse model of ciliary nerve ligation; 2nd presentation will present efficacy data of OK-201, a BAM8-22 peptide analog, in neuropathic corn...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Urcosimod
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
